Fennec Pharmaceuticals (FENC) Financial Statements & Analysis

Fennec Pharmaceuticals (FENC) Income Statement

Fennec Pharmaceuticals reported revenue of $44.64M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 6.1% from $47.54M a year earlier. Fennec Pharmaceuticals posted a net loss of $9.74M, compared with a net loss of $436.00K a year earlier. Gross margin was 91.6% and operating margin -14.1%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $17.87M, up 85.2% from the same quarter a year earlier.

Fennec Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Fennec Pharmaceuticals Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2015	FY 2014
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2015	Dec 2014
Revenue & Gross Profit
Revenue	44.64	47.54	21.25	1.54	0.00	0.17	0.00	0.00	0.00	-	-
Cost of Revenue	3.76	3.18	1.26	0.09	0.00	0.00	0.00	0.00	0.00	-	-
Gross Profit	40.88	44.35	19.99	1.62	0.00	0.17	0.00	0.00	0.00	-	-
Operating Expenses
Research & Development	0.25	0.31	0.06	3.53	4.98	5.11	5.74	5.01	1.94	0.26	0.36
Selling, General & Administrative	46.91	41.48	32.71	20.51	12.24	12.95	7.57	5.40	5.02	1.63	2.52
Operating Expenses	47.16	41.88	32.76	24.04	17.22	18.06	13.31	10.41	6.95	1.89	2.88
Operating Income	-6.28	2.48	-12.77	-22.59	-17.22	-17.89	-13.31	-10.41	-6.95	-1.89	-2.88
Other Income/Expense
Interest Income	0.79	1.59	0.44	0.20	0.05	0.09	0.32	0.00	0.00	-	-
Interest Expense	2.08	4.07	-3.68	-1.13	0.13	0.00	0.00	0.00	0.00	-	-
Other Income/Expense	-3.35	-2.55	-3.27	-1.13	-0.04	-0.22	0.24	0.52	-0.10	1.23	0.70
Income
Income Before Tax	-9.64	-0.07	-16.05	-23.71	-17.35	-18.11	-13.07	-9.89	-7.05	-0.66	-2.18
Income Tax Expense	0.11	0.37	0.00	0.00	0.00	0.00	0.00	-0.35	-0.05	-	-
Net Income	-9.74	-0.44	-16.05	-23.71	-17.35	-18.11	-13.07	-9.89	-7.05	-0.66	-2.18
Net Income - Continuous Operations	-9.74	-0.44	-16.05	-23.71	-17.35	-18.11	-13.07	-9.89	-7.05	-	-
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-6.18	4.80	-12.77	-22.59	-17.22	-18.10	-13.07	0.52	-0.10	-1.89	-2.88
EBIT	-6.28	2.57	-12.77	-22.59	-17.22	-17.89	-	-	-	-1.89	-2.88
Depreciation & Amortization	0.06	0.80	0.29	0.15	0.02	0.40	0.00	10.41	6.95	-	-
Earnings Per Share
Basic EPS	-	-	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-	-	-
Diluted EPS	-	-	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-	-	-
Basic Shares Outstanding	28.58	27.29	26.57	26.28	26.01	23.70	19.90	18.94	14.99	10.98	9.89
Diluted Shares Outstanding	28.58	27.29	26.57	26.28	26.01	23.70	19.90	19.02	15.01	10.98	9.89

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Fennec Pharmaceuticals Financial Statements

What was Fennec Pharmaceuticals's revenue in fiscal 2025?

Fennec Pharmaceuticals reported revenue of $44.64M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 6.1% from $47.54M a year earlier.

Is Fennec Pharmaceuticals profitable?

No. Fennec Pharmaceuticals reported a net loss of $9.74M in fiscal 2025. In fiscal 2024 it lost $436.00K.

What is Fennec Pharmaceuticals's operating margin?

Fennec Pharmaceuticals's operating income was −$6.28M on revenue of $44.64M in fiscal 2025, an operating margin of -14.1%, compared with 5.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition